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Abstract
Background: T helper 17 cells (TH-17) represent a lineage of effector T cells critical in host defence and autoimmunity. In
both mouse and human IL-1b has been indicated as a key cytokine for the commitment to TH-17 cells. Cryopyrin-associated
periodic syndromes (CAPS) are a group of inflammatory diseases associated with mutations of the NLRP3 gene encoding
the inflammasome component cryopyrin. In this work we asked whether the deregulated secretion of IL-1b secondary to
mutations characterizing these patients could affect the IL-23/IL-17 axis.
Methodology/Principal Findings: A total of 11 CAPS, 26 systemic onset juvenile idiopathic arthritis (SoJIA) patients and 20
healthy controls were analyzed. Serum levels of IL-17 and IL-6 serum were assessed by ELISA assay. Frequency of TH17 cells
was quantified upon staphylococcus enterotoxin B (SEB) stimulation. Secretion of IL-1b, IL-23 and IL-6 by monocyte derived
dendritic cells (MoDCs), were quantified by ELISA assay. A total of 8 CAPS and 11 SoJIA patients were also analysed before
and after treatment with IL-1b blockade. Untreated CAPS patients showed significantly increased IL-17 serum levels as well
as a higher frequency of TH17 compared to control subjects. On the contrary, SoJIA patients displayed a frequency of TH17
similar to normal donors, but were found to have significantly increased serum level of IL-6 when compared to CAPS
patients or healthy donors. Remarkably, decreased IL-17 serum levels and TH17 frequency were observed in CAPS patients
following in vivo IL-1b blockade. On the same line, MoDCs from CAPS patients exhibited enhanced secretion of IL-1b and IL-
23 upon TLRs stimulation, with a reduction after anti-IL-1 treatment.
Conclusion/Significance: These findings further support the central role of IL-1b in the differentiation of TH17 in human
inflammatory conditions.
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Introduction
T helper 17 (TH17) is a subset of effector CD4
+ T cells crucial
for the response to fungal and extracellular bacteria [1,2]. They
also play a pathogenetic role in several animal models of
autoimmune diseases [1,3], as well as in human chronic
inflammation [4–5]. IL-17 is known to induce the mobilization,
recruitment, and activation of neutrophils [5]. Moreover, it is able
to stimulate the expression of several proinflammatory cytokines
and chemokines by a broad range of cellular targets, including
epithelial cells, endothelial cells and macrophages [5].
Human TH-17 cells are defined by the expression of surface
markers such as CCR6 and CCR4 [6], CD161 [4] and IL-23R
[7], as well as by the production of different proinflammatory
cytokines such as IL-17A and IL-17F, IL-21, IL-22, TNF–a, IL-9 ,
IL-10 and IL-26 [5,8,9].
The differentiation of naı ¨ve T cells into pro-inflammatory TH17
is dependent on the extracellular environment in which T cells are
activated.
TGF-b and IL-6 have been indicated as the two key cytokines
for the in vitro differentiation of murine TH17 cells [10–12].
However, when the development of TH17 cells has been analyzed
in humans, a number of evidences showed the predominant role of
IL-1b (alone or in synergy with other cytokines, i.e. IL-23 and IL-
6) [4,6,7], raising the hypothesis that a dichotomy between mice
and humans exists [5].
Cryopyrin-associated periodic syndromes (CAPS) are a group of
rare inherited inflammatory disorders consisting in familial cold-
induced autoinflammatory syndrome (FCAS), Muckle-Wells
syndrome (MWS) and chronic infantile neurologic, cutaneous,
articular (CINCA) syndrome [also named Neonatal Onset Multi-
systemic Inflammatory Disease (NOMID)] [13]. These disorders
are associated with NLRP3 (or CIAS1) heterozygous mutations
which determines an abnormal in vitro secretion of IL-1b by
monocytes [14]. The specific inhibition of IL-1b leads to a
dramatic normalization of the inflammatory manifestations
[15,16] as well as to a strong in vitro reduction of IL-1b secretion
[17]. For this reason CAPS represent a suitable model to verify the
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20014actual role of IL-1b in the generation of TH17 cells in humans.
Here we report that exaggerated IL-1b secretion due to NLPR3
mutations affects the IL-23/IL-17 axis in CAPS patients,
providing further evidence of the role of IL-1b in TH17
differentiation.
Methods
A total of 11 CAPS (6 CINCA, 5 MWS) were enrolled in the
study (Table 1). Twenty-six systemic onset juvenile idiopathic
arthritis (SoJIA) patients with active disease and 20 aged-matched
healthy individuals were used as disease-and healthy -controls,
respectively. Samples were taken after informed consent approved
by ‘‘G. Gaslini’’ Ethical board.
CAPS patients displayed the following mutations of NLRP3
gene: T348M (2 patients), D303N (2 patients), E304K (2 patients),
M406I, N477K, E525K, I572F, R260W [18]. At the time of the
enrolment in the study, all CAPS patients were naı ¨ve from anti-IL-
1 and displayed an active phase of their disease, in terms of
presence of disease-related clinical manifestations and elevation of
acute phase reactants. Disease activity in SoJIA patients was
defined by the presence of at least two of the main clinical
manifestations (fever, arthritis, rash) and elevation of acute phase
reactants despite ongoing therapy with non steroidal anti-
inflammatory drugs, oral steroids and/or methotrexate. Peripheral
blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation using Fycoll from LympholyteH, Ceder-
lane. Eight CAPS patients and 11 SoJIA patients were evaluated
the day before and 7–10 days after anti-IL-1 treatment (Anakinra).
Flow cytometry
Thawed PBMCs were stained with the following antibodies:
allophycocyanin conjugated anti human CD4 (APC Beckton
Dickinson, BD), fluorescein isothiocyanate conjugated anti human
CD45RA (FITC Beckman Coulter), phycoerythrin conjugated
anti human CCR6 (PE, BD) and phycoerythrin conjugated anti
human CD161 (Beckman Coulter). Cells were incubated with
50 ml of PBS 1% FCS for 20 min at 4uC in the dark and acquired
with a FACSCanto cytometer. Data were analyzed with Flow-Jo
software. Quantification of circulating memory CCR6
+ and
CD161
+ was determined electronically gating on alive lympho-
cytes and expressed as the absolute number (number610
3/mm
3)
multiplying the relative percentage of the different subsets by the
peripheral lymphocytes count.
Quantification of TH17 producing cells
Freshly isolated or thawed PBMCs were stimulated overnight
with staphylococcus enterotoxin B (SEB, 100 ng/ml, Sigma
Aldrich), anti-CD28 (1 mcg/ml, BD), anti-CD49d (1 mcg/ml,
BD) Mabs in the presence of Brefeldin A (BFA 1 mcg/ml, Sigma
Aldrich), as described previously [19–21]. Surface staining of CD3
(PeCy5, BD), CD8 (APC-Cy7, BD) and intracellular staining of
IL-17 (eBiosciences) and IFN-c (BD) were performed according to
manifacturer’s instructions.
Generation and stimulation of monocyte-derived DCs
[MoDCs]
Peripheral blood CD14
+ monocytes were positively isolated
with CD14-specific micro-beads (Miltenyi Biotech). DCs were
obtained from monocytes after culture with granulocyte-macro-
phage colony-stimulating factor (GM-CSF, 50 ng/ml, Peprotech)
and IL-4 (20 ng/ml Peprotech). At day 7, DCs were cultured for
additional 48 h in 96-well flat bottom plates with Lypopolisaccaride
(LPS, 1 mg/ml, Sigma Aldrich), Staphylococcus Aureus (S.a 10
8/ml,
Invivogen) and Zymosan A (50 mg/ml, Sigma Aldrich).
Serum and supernatant cytokine detection
Levels of IL-1b, IL-23, IL-17 and IL-6 in culture supernatants
or sera were quantified by ELISA assay (eBiosciences) according to
the manufacturer’s instructions.
Statistical analysis
Differences among groups were evaluated using the non
parametric Kruskal-Wallis test. Post-hoc analysis was performed
with non-parametric U Mann-Whitney test. Comparison of
variables before and after treatment was performed with Wilcoxon
test.
Results
IL-17 and IL-6 serum levels and ex-vivo phenotype of
circulating CCR6
+ and CD161
+ memory CD4
+ T cells
Serum IL-17 was measured in 10 active NLPR3-mutated CAPS
patients compared to 20 healthy controls and 20 SoJIA patients.
As shown in Figure 1A, IL-17 was significantly higher in CAPS
patients (median 5,1 pg/ml range:0–14.4) when compared to
healthy controls [0.4 pg/ml, 0–6.5 pg/ml) (p=0.04). A slight
elevation of serum IL-17 was also observed in some active SoJIA
patients (1.9 pg/ml, 0–8.6 pg/ml), with no statistical differences
with either CAPS patients or healthy controls (Figure 1A).
CAPS patients displayed higher serum levels of IL-6 (median
8.4 pg/ml, 0–38 pg/ml) as well when compared to healthy
controls (median 2.5 pg/ml, 0–13.5 pg/ml) (P=0.02). Differently
from what observed for IL-17, active SoJIA patients showed a
significant elevation of serum IL-6 (median 54.3 pg/ml range:15–
230) with respect to CAPS patients and healthy controls (P,0.001)
(Figure 1B).
CCR6 and CD161 have been recently indicated as additional
markers to define TH17 producing cells [22] [4]. Thus, CCR6 and
CD161 expression was evaluated in circulating memory CD4
+ T
cells (CD4
+CD45RA
2) from 7 NLPR3-mutated CAPS patients, 10
healthy controls and 12 active SoJIA. The number of circulating
CCR6
+ memory CD4
+ T cells in NLPR3-mutated CAPS patients
Table 1. Clinical characteristics of CAPS and SoJIA patients at the moment of the study.
Male/Female
Age
(years; range)
Disease duration
(years; range)
CRP mg/dL
(mean, range) Rash
Active
Arthritis Fever
CAPS
(n=11)
7/4 11.7 (2.6–43) 10.6 (0.6–22.8) 5.2 (1.9–10.2) 10/11 8/11 6/11
SoJIA
(n=26)
16/10 7.6 (1.5–19.3) 3.6 (0.3–10.9) 12.3 (1.3–25) 11/26 23/26 16/26
doi:10.1371/journal.pone.0020014.t001
IL-17/IL-23 Axis in CAPS Patients
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20014(Figure 1C) tent to be higher than that found in the other two
subgroups, although the difference was not statistically significant.
Conversely, the absolute number of CD161
+ memory T cells was
comparable among the three subgroups (Figure 1D). The same
data were observed when the percentage of alive T lymphocytes
were evaluated (not shown).
Frequency of IL-17 and IFN-c CD4+ T cells in CAPS
patients
The frequency of IL-17 and IFN-c producing cells upon anti-
CD28, anti-CD49d and SEB stimulation was analyzed according
to the experimental protocol recently described by Milner et al.
[16]. As shown in Figure 2B, active CAPS patients displayed a
significantly higher absolute number (median 7,5 cells/mm
3,
range 2,9–9,5) of IL-17 producing cells compared to healthy
controls (median 1,34 cells/mm
3, range 0,4–5,4) (p=0.002) and
active SoJIA patients (median 1,31 cells/mm
3, range 0,3–5,2)
(p=0.003). The same results were also obtained when percentage
of IL-17 producing cells was assessed (CAPS: median 0,37%,
range 0,2–0,73; healthy donors: median 0,1%, range 0–0,28;
SoJIA: median 0,06% range 0,0–0,36) (P=0.01, see also
Figure 3D). Conversely, no differences in the absolute numbers
(Figure 2C) and percentages (not shown) of IFN-c producing T
cells was observed among the three subgroups.
Effect of anti-IL-1 treatment on serum IL-17 and
frequency of IL-17 producing cells
Most of the CAPS patients analyzed in the present study were
treated with IL-1 blockers, namely IL-1 receptor antagonist
(Anakinra). As previously shown, the treatment was able to
dramatically control the clinical manifestations of all treated
patients with a complete normalization of laboratory parameters
(hemogram and acute phase reactants) within two weeks [17].
The effect of anti IL-1 treatment on IL-17 serum concentra-
tions and on the frequency of IL-17 producing cells is shown in
Figure 3. A significant decrease of IL-17 serum concentration was
Figure 1. Analysis of IL-17 and IL-6 serum concentrations and peripheral CD4+ T cell phenotype. IL-17 (panel A) and IL-6 (panel B) serum
levels were measured in 10 active CAPS patients, 20 active SoJIA patients and 20 healthy controls by ELISA. C–D) Ex-vivo analysis of circulating CCR6
+
(panel B) and CD161
+ (panel C) memory T cells (CD4
+CD45RA
2) in the same three subgroups. Heterogeneity test among groups was evaluated using
the non parametric Kruskal-Wallis test (upper right of each graph). Post-hoc analysis with non-parametric U Mann-Whitney test revealed the
difference among the three subgroups.
doi:10.1371/journal.pone.0020014.g001
IL-17/IL-23 Axis in CAPS Patients
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20014observed in all CAPS patients after 7–10 days of treatment
(Figure 3A). A slight, albeit non significant, decrease was also
observed when analyzing IL-6 serum concentration (Figure 3B).
Accordingly, treatment with IL-1 blockers was able to normalize
the frequency of IL-17 producing cells after SEB stimulation in
NLPR3-mutated CAPS patients, either when evaluated as
absolute number [Figure 3C) or percentage of CD4+ T cells
(Figure 3D).
In the present study, 11 SoJIA patients were analyzed before
and after anti-IL-1 treatment. After 7–10 days of treatment a
significant reduction of IL-6 was observed in anti-IL-1 treated
patients (Figure 3B). As previously observed, the long term effect of
IL-1 blockade in SoJIA patients is rather variable [23]. In the
subsequent follow-up, 7 SoJIA patients displayed a complete
response, with a dramatic and persistent control of systemic and
articular manifestations, whereas the remaining 5 patients were
incomplete or non-responders [23]. Despite a few SoJIA responder
patients displayed a decrease serum levels of IL-17 and frequency
of IL-17 producing cells after anti-IL-1 treatment, a retrospective
evaluation was not able to find any significant differences in the
serum levels of IL-17 and IL-6, nor in the frequency of IL-17
producing cells before anti-IL-treatment between responder and non
responder SoJIA patients (data not shown).
Monocytes-derived dendritic cells from CAPS patients
display an increased secretion of IL-1b and IL-23
Since CAPS is associated with a primary defect of the innate
immune system, it is conceivable that the TH17 skewed
phenotype observed in CAPS patients could be related to an
aberrant influence on T cell differentiation by antigen-presenting
cells rather than by an intrinsic T cells defect [24]. Thus, we
analyzed the in vitro IL-1b, IL-23 and IL-6 secretion by MoDCs
cells after stimulation with TLR ligands in 4 active CAPS patients
(2 CINCA and 2 MWS) with NLPR3 mutation, 4 active SoJIA
patients and 9 healthy controls. After stimulation with single
TLR-ligand (e.g. LPS), DCs produced variable amount of IL-6
but little of IL-1b and IL-23 either in healthy controls, CAPS and
SoJIA patients (data not shown) [25]. Nonetheless, Zymosan,
which simultaneously binds to TLR2 dectin-1 and dectin 2 [26–
27] was able to induce the secretion of detectable amounts of all
three cytokines.
Figure 2. CAPS patients show an higher absolute number of IL-17 producing cells after in vitro expansion. A) Dot plot electronically
gated on alive CD4
+ T cells of one representative CINCA patient, one systemic onset juvenile idiopathic arthritis (SoJIA) patient and one healthy
control B–C) Absolute number of IL-17 (panel B) and IFN-c (panel C) producing cells in 7 NLPR3-mutated CAPS and 12 SoJIA active patients and in 9
age-matched healthy controls. Heterogeneity test among groups was evaluated using the non parametric Kruskal-Wallis test (upper right of each
graph). Post-hoc analysis with non-parametric U Mann-Whitney test revealed the difference among the three subgroups.
doi:10.1371/journal.pone.0020014.g002
IL-17/IL-23 Axis in CAPS Patients
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significantly higher amount of IL-1b and IL-23 compared to 10
healthy controls and 4 SoJIA patients, whereas no relevant
differences were observed in IL-6 secretion among the three
subgroups.
Remarkably, after 7 days of treatment with IL-1 blockers, in all
CAPS patients we observed a marked reduction of both IL-1b
(pre-treatment median 83 ng/ml, range 28.5–148; post-treatment
median 24.2, range 20–104) and IL-23 (pre-treatment median
1348.6 ng/ml, range 261–2048; post-treatment median 459.4,
range 106–1038) secretion by MoDCs (data not shown).
Discussion
Given the growing evidence supporting the central role of the
IL-1b in the commitment of IL-17 producing cells [6], in the
present study we analyzed the IL-23/IL-17 axis in CAPS patients
in order to explore a possible involvement of IL-1b in TH-17
differentiation in this context.
The protein mutated in CAPS, namely Cryopyrin is a key
protein of the inflammasome, a multi-protein complex responsible
for activation of the IL-1 converting enzyme (ICE) (or Caspase-1),
which in turn converts pro-IL-1b to the mature, active 17 kDa
form [28]. In response to a broad range of stimuli, cryopyrin
oligomerizes and binds the adaptor protein ASC (Apoptosis
associated Speck-like protein containing a CARD). This associa-
tion activates directly two molecules of Caspase-1 which, in turn,
convert pro-IL-1b to the mature, active 17 kDa form. Therefore,
activated cryopyrin induces the release of the active form of IL-1b
[14,28,29].
NLPR3 mutations are associated with its gain of function with a
consequent excessive production of IL-1b [14,30] even in absence
of a second signal, such as extracellular adenosine triphosphate
(ATP) [17]. Due to the pleiotrophic proinflammatory effect of IL-
1b, the specific inhibition of IL-1b is able to dramatically dampen
the severe systemic inflammatory picture of CAPS patients
[15,16].
In contrast to what previously observed in mice models [10,11],
studies in humans have pointed out the potential pivotal role of IL-
1b, together with IL-23 and IL-6, in the differentiation of human
naı ¨ve T cells into IL-17 producing cells [4,6,7]. This hypothesis
has been disputed by other authors supporting the crucial role of
TGF-b in the differentiation of TH-17 in humans [31].
Figure 3. Effect of anti-IL-1 treatment on IL-17 and IL-6 serum levels and Th17 frequency. Variation of IL-17 (panel A) and IL-6 (panel B)
serum levels after anti-IL-1 treatment in 8 CAPS patients and 11 SoJIA patients (7 responders and 5 non responders). The decrease frequency of IL-17
producing T cells after anti-IL-1 treatment is reported either as absolute number (Panel C) and percentage of alive lymphocytes (Panel D). Statistical
analysis was performed using non-parametric Wilcoxon-Test.
doi:10.1371/journal.pone.0020014.g003
IL-17/IL-23 Axis in CAPS Patients
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human monogenic diseases, represents a powerful tool to
investigate the possible involvement of IL-1b in the commitment
of naı ¨ve T cells towards IL-17 producing cells during the course of
chronic inflammatory diseases.
In the present study, several evidences suggest the existence of a
TH17 skewed phenotype in NLPR3-mutated CAPS patients: i)
CAPS patients showed increased levels of serum IL-17, ii)
stimulated PBMCs displayed higher frequency of IL-17 producing
cells compared to healthy controls; iii) monocytes-derived
dendritic cells from CAPS patients displayed increased production
of IL-1b and IL-23. Notably, either IL-17 serum concentrations or
the increased number of IL-17 producing cells observed in CAPS
patients were clearly down-modulated by anti IL-1b treatment,
suggesting a possible IL-1 dependency of the TH17 skewed
phenotype observed in CAPS patients. Moreover, when mono-
cyte-derived DCs from the same CAPS patients were evaluated 1
week after anti-IL-1b treatment, a clear reduction of the secretion
of both IL-1b and IL-23 was found, as already observed for IL-1b
in NLRP3-mutated monocytes after in vivo treatment with IL-1
blockers [17].
The inhibitory role of anti-IL-1 treatment in the TH17
differentiation has been already observed in previous studies.
The in vitro use of IL-1ra was able to decrease the amount of IL-17
secreted by naı ¨ve T cells polarized with the supernatants of MoDcs
upon 48 h of Zymosan stimulation [32]. Moreover, PBMCs from
celiac patients showed an evident down-modulation of IL-23 in
presence of IL-1Ra [33]. This latter observation, supports the
hypothesis that the over-expression of IL-23 observed in CAPS
patients could be related to an IL-1b dependent mechanism, likely
associated to the activation of the inflammasome. In our study the
pattern of IL-6 secretion by MoDcs, another cytokine which is
classically considered to be crucial to the TH17 differentiation, did
not show the same behavior observed for IL-1b and IL-23. Even if
IL-6 is considered to be down-stream o IL-1b, its expression is not
influenced by the activation of the inflammasome. It is therefore
conceivable that, at least in this experimental setting, NLRP3-
mutated MoDC’s did not show an over secretion of IL-6, as also
observed in circulating monocytes from CAPS patients (Carta et
al., manuscript in preparation).
Our study performed in a genetically driven IL-1b mediated
disease showed that, at least in CAPS, IL-1b and IL-23 may play
the major role in the differentiation of TH17 cells.
The different behavior observed in an other systemic inflam-
matory disease such as SoJIA, let us make the hypothesis that the
above mentioned findings are likely secondary to the genetic defect
of the NLRP3 gene rather than to a non-specific influence of the
ongoing inflammation.
SoJIA is a multifactorial, inflammatory disease that share a
number of clinical features (systemic inflammation, arthritis, rash,
persistent elevation of acute phase reactants) with CAPS. The
pathogenesis of SoJIA is still rather controversial even taking into
account the likely heterogeneity of this condition. A number of
experimental evidences supports the pivotal pathogenic role of IL-
6 in SoJIA [34–37]. These findings are in line with the efficacy of
IL-6 blockade observed in this condition [38,39].
However, as observed in other IL-6 mediated disease such as
Castelman’s disease and smoldering multiple myeloma [40,41], a
variable percentage of these patients (from 40 to 87% according to
the different studies) also shows a dramatic and persistent response
to anti-IL-1 blockade, with the rest of SoJIA patients being
resistant to such a treatment [23,42,43],
The different rate of response to anti IL-1 treatment observed in
SoJIA patients may explain the variability of the findings
concerning the actual pathogenic role of IL-1 in this latter disease.
In some studies, gene expression analysis revealed the presence of
a prevalent IL-1b signature in SoJIA [42,44]. The same picture
Figure 4. elevated level of IL-1b and IL-23 secreted by MoDCs
of CAPS patients upon Zymosan stimulation. Secretion of IL-1b
(A), IL-23 (B) and IL-6 (C) by MoDs upon 48 hours of challenge with or
without Zymosan in 4 CAPS patients, 10 healthy controls and 4 active
SoJIA patients. Bold horizontal lines represent median values. Boxes
contain the 50% of values falling between the 25th and 75th
percentiles, whiskers lines that extend from the boxes represent the
highest and lowest values for each subgroups. Statistical analysis was
performed using non-parametric U Mann-Whitney test.
doi:10.1371/journal.pone.0020014.g004
IL-17/IL-23 Axis in CAPS Patients
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confirmed the prevalent role of genes of innate immunity in this
condition. Similar variability was also observed when the pattern
of secretion of IL-1b from SoJIA PBMCs and/or monocytes was
compared to healthy controls [23,42,48]. In any case, when
compared to active NLRP3-mutated CAPS patients, monocytes
from active SoJIA secrete lower amounts of IL-1b [17,23] and
displayed a different kinetics of secretion [49], independently from
the pattern of clinical response to IL-1b blockade [23]. These
latter observations do not exclude the possibility that in SoJIA the
paracrine secretion of IL-1b in privileged sites can induces
different target cells to produce large amounts of IL-6, thus
explaining the good response to IL-1 blockade, as observed in
other ‘‘IL-6-driven’’ diseases [40,41,50].
In the present study the serum concentrations of IL-6 in CAPS
patients, that we found similar to those reported by Goldbach-
Mansky et al. [16], were significantly lower when compared to
active SoJIA patients. This finding is in agreement with the normal
secretion of IL-6 observed in CAPS MoDc’s and monocytes (Carta
et al. manuscript in preparation) and may explain the anecdotal
poor response to IL-6 blockade in CAPS patients [51].
In the present study, SoJIA patients showed a less evident
elevation of IL-17 during the active phase of disease and no
significant increase in the frequency of IL-17 producing cells. Our
observation do not exclude per se the possible contribution of the
IL-17/IL-23 axis in.
SoJIA. Indeed, as already observed in RA and other forms of
JIA [5,52], SoJIA patients display an increased frequency of IL-17
producing cells in synovial fluid when compared to peripheral
blood (not shown). The finding of a TH17 skewed phenotype in a
pure IL-1 driven disease such as CAPS further confirms the pivotal
role of IL-1b in the TH17 differentiation in human inflammatory
diseases. Interestingly, recent evidences coming from different
studies have pointed out the pivotal role of IL-1b in the in vivo and
in vitro differentiation of naı ¨ve T cells into TH-17 cells also in mice
[24,53,54], disputing the existence of a actual dichotomy between
mice and humans [54]. Even if CAPS represents the example of an
inflammatory diseases predominantly driven by a primary
deregulation of the innate arm of the immune response, our study
illustrate its possible consequences on the adaptive response.
Whether the expansion of TH17 phenotype observed in CAPS
patients is simply an epiphenomenon secondary to the over-
secretion of IL-1b due to NLPR3 mutations or it may contribute to
the maintenance of chronic inflammation, likely through the
influence of IL-17 in neutrophils mobilization and recruitment, is
still unclear.
Two recent parallel studies using NLRP3 mutant knock-in
mouse strains were not able to clarify this issue. In fact, the NLPR3
A352V and L353P knockin mouse were characterized by an early
lethality and by a minimal involvement of T cells and IL-17 and
IL-22 expression in either spleen and skin infiltrate [55].
Conversely, the generation of the NLPR3-R258W mice was
associated with a more prolonged survival and with the
development of a spontaneous skin inflammation with a prevalent
neutrophilic infiltration, but with an evident lymphoid component
that was characterized by a TH17 cytokine predominance [56].
In conclusion, the present study performed in a genetically
driven IL-1b mediated disease supports the pivotal role of IL-1b in
TH17 differentiation in humans, and suggest the hypothesis that a
continuous cross-talk between innate and adaptive immunity may
contribute to the development and maintenance of chronic
inflammation in these conditions.
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